Market's Best Report: meningococcal vaccines - germany drug forecast and market analysis to 2022
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

Market's Best Report: meningococcal vaccines - germany drug forecast and market analysis to 2022

on

  • 334 views

...


PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022SummaryGlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022.
To Read The Complete Report Kindly Visit: http://www.marketresearchreports.biz/analysis/170313
For All Latest Reports Kindly visit: http://www.marketresearchreports.biz

Statistics

Views

Total Views
334
Views on SlideShare
334
Embed Views
0

Actions

Likes
1
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Market's Best Report: meningococcal vaccines - germany drug forecast and market analysis to 2022 Document Transcript

  • 1. PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022 GlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines Germany Drug Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022. GlobalData predicts that relative patient share for the three MenC conjugate vaccines will remain unchanged for the duration of the forecast period because Nuron Biotechs Meningitec, Novartis Menjugate kit, and Baxters NeisVac-C possess nearly identical clinical profiles and price points. The MenC conjugate patient share is largely determined by prescriber preference in Germany and therefore is not expected to change drastically during the forecast period. Scope Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key drugs in Germany including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for the top drugs in Germany from 2012-2022. Analysis of the impact of key events as well the drivers and restraints affecting Germany Meningococcal Vaccines market. Reasons to buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of drug performance Obtain sales forecast for drugs from 2012-2022 in Germany table Of Contents 1 Table Of Contents 1 1.1 List Of Tables 3 1.2 List Of Figures 3 2 Executive Summary 4 2.1 Sales For Meningococcal Vaccine In Germany 4 2.2 What Do The Physicians Think? 6 3 Introduction 7 PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022
  • 2. 3.1 Catalyst 7 3.2 Related Reports 8 3.3 Upcoming Related Reports 10 4 Disease Overview 10 4.1 Etiology And Pathophysiology 11 4.1.1 Etiology 11 4.1.2 Pathophysiology 12 4.2 Symptoms 13 4.3 Prognosis 14 5 Disease Management 14 5.1 Meningococcal Immunization Policy 15 5.2 Germany 17 5.2.1 Meningococcal Immunization Recommendations And Policies 17 5.2.2 Clinical Practice 18 6 Competitive Assessment 18 6.1 Overview 18 6.2 Strategic Competitor Assessment 18 6.3 Product Profiles Major Brands 20 6.3.1 Menveo 20 6.3.2 Nimenrix 24 6.3.3 Meningitec 27 6.3.4 Menjugate 30 6.3.5 Neisvac-c 33 6.3.6 Bexsero 35 7 Opportunity And Unmet Need 37 7.1 Overview 37 7.2 Unmet Needs 38 7.2.1 Unmet Need: Protection Against Serogroup B Disease 38 7.2.2 Unmet Need: A Pentavalent (menabcwy) Vaccine 38 7.2.3 Unmet Need: More Cost-effective Vaccines 40 7.2.4 Unmet Need: Improved Duration Of Immunity In Children And Adolescents 40 7.2.5 Unmet Need: Immunogenic Infant Vaccines 42 7.2.6 Unmet Need: Improved Vaccination Coverage Rates 43 7.2.7 Unmet Need: Increased Patient Awareness And Education 44 7.3 Unmet Needs Gap Analysis 45 7.4 Opportunities 46 7.4.1 Opportunity: Broadening Serogroup Protection With New And Existing Antigen Combinations 46 7.4.2 Opportunity: Improving Immune Response Duration With Adjuvants 47 7.4.3 Opportunity: Developing More Cost-effective Vaccines By Partnering With Manufacturers In Emerging PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022
  • 3. Markets 48 8 Pipeline Assessment 48 8.1 Overview 48 8.2 Promising Vaccines In Clinical Development 48 8.2.1 Mnb Rlp2086 52 8.3 Promising Vaccines In Early Clinical Development 56 8.3.1 Meninge Acyw Conj. 56 8.3.2 Menabcwy 60 8.3.3 Menc Conjugate 62 8.3.4 Heptavalent Dtp-hib-hepb-ipv-menc 65 9 Market Outlook 67 9.1 Germany 67 9.1.1 Forecast 67 9.1.2 Key Events 70 9.1.3 Drivers And Barriers 71 10 Appendix 72 10.1 Bibliography 72 10.2 Abbreviations 82 10.3 Methodology 84 10.4 Forecasting Methodology 84 10.4.1 Vaccine Coverage 85 10.4.2 Vaccine Approval Vs. Routine Schedule Inclusion 85 10.4.3 Vaccines Included 86 10.4.4 Key Launch Dates 87 10.4.5 General Pricing Assumptions 88 10.4.6 Individual Vaccine Assumptions 89 10.4.7 Pricing Of Pipeline Agents 94 10.5 Physicians And Specialists Included In This Study 95 10.6 About The Authors 98 10.6.1 Authors 98 10.6.2 Reviewers 98 10.6.3 Global Head Of Healthcare 98 10.7 About Globaldata 99 10.8 Contact Us 99 10.9 Disclaimer 99 Market Research Report(http://www.marketresearchreports.biz/) Marketresearchreports.biz is the most comprehensive collection of market research reports. Marketresearchreports.biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries. PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022
  • 4. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.com Website: www.marketresearchreports.biz PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022